SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).
Abstract No : 5002
Abstract Type : Oral Abstract Session
Indication : Papillary Renal Cell Carcinoma (PRCC)
Intervention : Savolitinib
Company : AstraZeneca
Technology : c-MET Tyrosine Kinase Inhibitor
After external data on predicted PFS with sunitinib in pts with MET-driven disease became available, study enrollment was closed. At data cutoff (Aug 2019), only 60 of the planned 180 pts were randomized (savolitinib n = 33; sunitinib n = 27). Most had chromosome 7 gain (savolitinib 91%; sunitinib 96%) and no prior therapy (savolitinib 85%; sunitinib 93%). PFS, OS, and ORR were numerically improved with savolitinib vs sunitinib (Table). CTCAE grade $3 adverse events (AEs) were reported in 42% and 81% of pts; dose modifications were related to AEs in 30% and 74% of pts with savolitinib and sunitinib respectively. After discontinuation, 36% of all savolitinib and 19% of all sunitinib pts received subsequent anticancer therapy
Although pt numbers and followup were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile vs sunitinib, with fewer grade $3 AEs and fewer dose modifications required. Sunitinib performance was poorer than expected based on external retrospective data. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted
Savolitinib demonstrated encouraging efficacy and an improved safety profile vs sunitinib, with fewer grade 3 AEs and fewer dose modifications required. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.